Urine protein profiling with surface-enhanced laser-desorption/ ionization time-of-flight mass spectrometry.
of these proteins cannot only improve our knowledge of kidney physiology [1] , but can also allow the identification of novel proteins associated with pathologic states. Indeed, it may be possible to identify potential biomarkers to diagnose and/or monitor renal disease [2] [3] [4] .
At present, there are several techniques to identify and compare the expression of proteins, each with advantages and disadvantages. The most established method is protein separation by two-dimensional gel electrophoresis (2-DE) followed by in-gel digestion and peptide mass fingerprinting by mass spectrometry. This method allows for the comparison of the relative abundance of proteins. In recent literature, Thongboonkerd et al [5] identified 67 protein forms of 47 unique proteins in normal urine by 2-DE. However, there are several limitations of 2-DE as a separation method for proteomic studies. The resolvable range of molecular weights is limited at both ends, with a bias toward high-abundance proteins. In addition, the technique requires relatively large amount of sample, is labor-intensive, and good gel-to-gel reproducibility can be hard to achieve [2, 6] . Thus, this approach is not optimal for high throughput profiling. An alternative approach uses liquid chromatography as the separation step upstream from the mass spectrometer (LC-MS). Using this approach, Spahr et al [7] identified 124 gene products (proteins and translations of expressed sequence tags) in normal urine samples. While this technique provides information about the protein content of the samples, little information about their relative abundance can be obtained unless the proteins/peptides are labeled first by isotope-coded affinity tags [8, 9] or other protein/peptide labeling techniques. Furthermore, this method is still labor-intensive and has limited throughput.
Surface-enhanced laser-desorption/ionization time-offlight mass spectrometry (SELDI-TOF-MS) addresses some of the limitations of both 2-DE and LC-MS. It combines matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) to surface chromatography. Specifically, a sample is applied to a chip surface carrying a functional group. After incubation, proteins that do not bind to the surface are removed by a simple wash step, and bound proteins are analyzed by mass spectrometry. This approach, in contrast to the others described, allows for high throughput profiling of multiple clinical samples. In this article, technical issues, pitfalls, and limitations of this technique in protein profiling normal urine samples are described and discussed.
METHODS

Urine collection and storage
Second-morning urine from healthy men and women were collected in two different containers. The first 10-20 mL of urine was considered as first-void urine, the following 50-80 mL as midstream urine. Unless otherwise stated, urine was centrifuged in a fixed-angle centrifuge for 10 minutes at 2000 rpm (900g), the supernatant was transferred into 2 mL cryo-tubes (Gordon Technologies, Inc., Missisauga, Ontario, Canada), and stored at -70
• C. All samples were obtained with informed consent and ethics approval of the University of Manitoba IRB.
Urine sediments
Ten mL of freshly collected urine was centrifuged for 10 minutes at 2000 rpm. The pellet was analyzed with a phase-contrast microscope at 400× augmentation and is reported as cells per high-power field (hpf).
Protein chip preparation and reading
Normal phase chips (ProteinChip NP20; Ciphergen, Freemont, CA, USA), which bind proteins through hydrophilic and charged residues (including serine, threonine, and lysine), were used for the analysis. Urine samples were thawed on ice, shortly vortexed, and centrifuged for 5 minutes at 10,000 rpm (to remove remaining cell particles). Five lL of urine supernatant were applied in duplicate to the chip and incubated for 20 minutes in a humidity chamber. Spots were then washed three times with 5 lL high-performance liquid chromatography (HPLC)-grade water and air-dried for 10 minutes. Saturated a-cyano-4-hydroxycinnamic acid (CHCA; Ciphergen) and sinapinic acid (SPA; Ciphergen) were prepared in 50% acetonitrile/0.5% trifluoroacetic acid according to the manufacturer's instructions. Dilutions of 20%, 35%, and 50% were used. One lL of matrix solution (35% CHCA, unless otherwise specified) was applied to each spot and air-dried. Unless stated otherwise, chips were read with the following SELDI-TOF-MS instrument (ProteinChip Reader II; Ciphergen) settings: Laser intensity 230; detector sensitivity 6; detector voltage 1700 V; positions 15 to 85 were read with an increment of 5 (resulting in 15 different sampling positions); 16 laser shots were collected on each position (total shots collected and averaged: 240/sample); eight warming shots were fired at each position, which were not included in the collection; the acquired mass range was from a massover-charge (m/z) ratio of 0 to 80,000; lag time focus of 900 ns. Calibration was done externally with a mixture of 4 proteins with masses ranging from 2 to 16 kD. After baseline subtraction and normalization, peak labeling was performed with the ProteinChip Software (version 3.1) for peaks with a signal-to-noise (S/N) ratio of ≥3 in the m/z range from 2000-25,000.
RESULTS
Evaluation of reproducibility
It is critical to evaluate the reproducibility of urine protein profiling using the SELDI-TOF-MS approach before establishing whether the urine protein profiles differ in various clinical states. Reproducibility was evaluated by applying one urine sample to 14 spots and reading the spots using the protocol described above. The total number of detected peaks with an S/N-ratio ≥3 was 25 peaks/ spectrum (range, 23-29). Fourteen peaks common to all spectra were selected and compared with regard to their peak intensity by calculating the coefficient of variation. They ranged from 8% to 30%, with the lowest variation seen in the high intensity peaks and the higher variation seen in lower intensity peaks (Fig. 1A) . This is expected, as small differences in low intensity peaks (e.g., 1.0 vs. 0.5) have a large influence on the calculated coefficient of variation. Independent of the software assignment of protein peaks, it is important to conduct manual inspection of the spectra, to determine whether a specific peak is present. Low intensity peaks with an S/N-ratio near the selected detection threshold (i.e., ≥3) can be unlabelled and undetected by the software (Fig. 1B) .
Impact of extrinsic factors on reproducibility and peak detection of urine protein profiles
The impact of matrix on the urine protein profile was determined by comparing different dilutions of CHCA and SPA (20%, 35%, 50%, and 100%) with the otherwise unchanged protocol stated above. In the range from 2-25 kD, 22, 26, 19, and 16 peaks were detected using 20%, 35%, 50%, and 100% CHCA, respectively. In contrast, 13, 19, 11, and 10 peaks were detected using 20%, 35%, 50%, and 100% SPA. Peak intensity below 8-10 kD was higher with CHCA, whereas SPA yielded higher peak intensities above 8-10 kD (urine protein profiles not shown).
The impact of spot sampling protocols was determined by comparing three different spot sampling protocols with respect to peak detection in undiluted and diluted Fourteen peaks common to all spectra were selected and compared with regard to their peak intensity by calculating the coefficients of variation. They ranged from 8% to 30%, with the lowest variation seen in the high-intensity peaks and the higher variation seen in lower intensity peaks. (B) Parts of 4 randomly selected spectra from the obtained 14. Manual inspection of the spectra showed the presence of an unlabelled peak (circle in insert), although the spectra look the same by "eyeball."
urine: protocol 1 (standard protocol; see above); protocol 2 (standard protocol modified to sample on only 5 different positions for a total of 80 shots/sample); protocol 3 [standard protocol modified to use a higher detector sensitivity (10 instead of 6)]. Protocol 1 detected 34 peaks in undiluted urine, whereas protocols 2 and 3 detected only 21 and 26 peaks, respectively. In diluted urine (urine creatinine 3.75 mmol/L) the peak counts were 20, 11, and 13, respectively (urine protein profiles not shown).
If the SELDI-TOF-MS approach is to be used in the assessment of clinical samples, it is important to assess the stability of the urine proteins before analysis. First-void and midstream urine samples from three females and three males were analyzed within 2 hours from the time of collection, after storage for three days at room temperature, and after three days at 4
• C. In all six samples, only minor differences in the midstream urine protein profiles could be detected after storage for three days at 4
• C. However, in three first-void urines (two female, one male), storage for three days at room temperature or at 4
• C changed the spectra considerably. A series of new peaks in the low-molecular weight range were detected (Fig. 2) . Storage of the urine samples at −70
• C did not change the spectra compared with those obtained before freezing. Furthermore, almost the same spectra could be generated after four freeze-thaw cycles; however, a loss of peaks was observed after the fifth freeze-thaw cycle (Fig. 3) . freeze-thaw cycles were unchanged, but an increasing loss of intensity in some peaks was detected (↓). After the fifth freeze-thaw cycle some weak intensity peaks were not detected (−).
Impact of intrinsic factors on normal urine protein profiling
A potential confounding variable in the clinical setting is if a urine sample is first-void or midstream. In all three urine samples from males, there were almost no differences between the protein profile of first-void and midstream urine (Fig. 4A) . However, in all three urine samples from females, there are prominent peaks between 3.3 and 3.5 kD in the first-void urine fraction. These peaks are greatly diminished in the midstream urine sample, together with other changes in peak intensities (Fig. 4B) . Three of these peaks with average masses of 3370.3, 3441.2, and 3484.3 d are consistent with the masses of the a-defensins 2, 1, and 3, respectively.
Another confounding variable in urine proteomic analysis is the presence of blood in urine. It can be present in urine under normal conditions (e.g., menstruation) or in association with urogenital tract pathologies. To investigate the impact of blood on the normal urine profile, we spiked 500 lL urine with 10 lL blood, which resulted in a red coloring of the sample [sediment analysis showed >100 red blood cells (RBC)/hpf]. In the subsequent analysis by SELDI-TOF-MS, four major peaks were detected (Fig. 5B) , which are consistent with the masses of the hemoglobin a-and b-chains and their doubly charged ions. Based on the virtual disappearance of these peaks after sample centrifugation before SELDI-TOF-MS analysis, it is likely that these peaks represent hemoglobin. They were easily detectable as the most intense peaks up to a 1:128 dilution of this sample, corresponding to 10 lL blood in 64 mL diluted urine (urine protein profiles not shown). However, even when the RBC were removed by centrifugation, the urine was still contaminated with serum proteins. This is suggested by the presence of peaks with masses consistent with albumin in the urine protein profile (Fig. 5C) .
A dilute urine sample may limit the ability to detect the normal urine protein profile. To address the issue of urine concentration, urine was sampled from a healthy male with a body weight of 75 kg after 20 hours of no fluid intake. The measured urine creatinine was 15 mmol/L and the total protein was 0.11 g/L. At another time point, First-void and midstream urine protein profiles obtained from three females and three males. In males, both urine samples had similar protein profiles, whereas in females there are significant differences. The most prominent difference in female first-void urine are three peaks at 3370.3, 3441.2, and 3484.3 d (↓), which are consistent with the masses of the a-defensins 2, 1, and 3, respectively (Swiss-Prot P59665+P59666; 3371.9, 3442.5, 3486.5 d). The calculated mass accuracy of the surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) in this example is < 0.07%, which is within the limits given by the manufacturer (<0.1%).
the same individual was challenged with 4 L of fluid over 2 hours, leading to dilute urine with a creatinine of 0.9 mmol/L and a total protein of 0.03 g/L. While the concentrated urine showed the normal peak profile (Fig. 6A) , the dilute urine sample showed only three peaks in the range from 2-25 kD (Fig. 6E) . To determine the detection threshold of the normal urine profile, the concentrated urine sample was serially diluted. At a 1:2 dilution, which corresponds to a urine output of 2 L/day [calculated in our test person by: creatinine production/day (0.2 mmol/kg/day × 75 kg) divided by urine creatinine (7.5 mmol/L) = 2 L/day] the profile remained unchanged (Fig. 6B) . A progressive loss of urine profile peaks started with a 1:4 dilution. The 1:16 dilution showed a spectrum similar to the urine profile obtained after the fluid challenge (Fig. 6E ).
Protein quantification with SELDI-TOF-MS
To determine if either the spectral peak intensity or area provides a means for reliable protein quantification, serial dilution of a single protein (ubiquitin, 8565 d) was performed. There was an excellent correlation between the amount of protein in the sample and peak intensity (r 2 = 0.95) or the area under the peak (r 2 = 0.98) in nonnormalized spectra (Fig. 7A ). Even in a mixture containing four other proteins, the correlation was maintained (r 2 = 0.99 for peak intensity and for the area under the peak), but the peak intensities were 10 times lower with the same amount of ubiquitin (Fig. 7B) . When a complex protein mixture (i.e., normal urine with a protein concentration of 110 mg/L) was spiked with 1.0, 0.1, and 0.01 pmol/lL ubiquitin, only the first two concentrations of ubiquitin were detectable (Fig. 7C) . The peak intensity dropped from 0.32 (1.0 pmol/lL) to 0.09 (0.1 pmol/lL), which is only a 3.5 times decrease instead of the expected 10 times. Because only two measurements of peak intensity were obtainable, no correlation was calculated.
DISCUSSION
In order to use SELDI-TOF-MS as a high throughput urine protein profiling methodology, it is critical to define those factors that affect reproducibility, as well as identify the confounding variables that affect the detection of proteins that are known to be present in the sample.
Extrinsic factors
The most important extrinsic factors that influence reproducibility and peak detection are the matrix composition and the instrument settings. Matrix allows for efficient ionization and vaporization of proteins [10] . The most popular matrices for the SELDI-TOF-MS system are SPA and CHCA. Saturated SPA is preferable for looking at masses above 10-20 kD, while 10%-20% CHCA provides the best resolution for proteins/peptides up to about 5 kD. For urine protein profiling from 2-25 kD, more peaks and a higher degree of resolution were observed with 35% CHCA. Instrument settings such as detector sensitivity, detector voltage, and laser intensity have to be determined individually. The higher the detector sensitivity and voltage or the laser intensity, the better the detection of high-mass proteins. This is accompanied by an increase in background noise, which limits detection of low intensity peaks. The number of positions sampled on a spot is an important parameter for optimal peak detection. Ideally, all proteins are distributed homogeneously on the spot and are crystallized homogeneously in the matrix. If so, one would expect to generate the same spectra at every position. From the three spot sampling protocols it is clear that there are "hot positions," where proteins are clustered on the spot leading to the detection of an abundance of peaks with a high intensity. Similarly, there are "cold positions," where only few or even no peaks are detected. Unfortunately, "hot position" sampling may not accurately profile low abundant proteins due to ion suppression that can occur due to high abundant proteins. Therefore, the most representative spectra for a given urine sample is achieved by sampling many different spot positions and combining the data. This is especially true for dilute urine samples.
The stability of urine proteins under various storage conditions is important to know. Recent studies have found no or just small changes in albumin-, retinolbinding protein-, N-acetyl glucosaminidase-, IgG-and kappa/lambda light-chain concentrations after storage at room temperature, 4
• C, −20
• C, and −70 • C [11] [12] [13] [14] . Our experiments using SELDI-TOF-MS found that up to four freeze-thaw cycles at −70
• C did not alter the urine protein profile significantly; thereafter, peak intensities became weaker. The protein profiles of all midstream urine samples remained almost unchanged after storage for three days at 4
• C, whereas three of six first-void urines underwent major changes. First-void urine can have significant bacterial contamination, resulting in either urine protein degradation and/or contamination with bacterial proteins within a few days.
Intrinsic factors
Midstream urine is the standard for almost all urine analysis. In a clinical setting, there are always urine samples that are not midstream urines. Therefore, knowing the variation in urine protein profiles that may occur between first-void and midstream urines is important. There were no clear differences between first-void and midstream urine in males, whereas in females, variations were easily detectable. For example, a peak cluster between 3.3 and 3.5 kD (consistent with the masses of the a-defensins)
is present in female first-void urine in high intensity. This peak cluster is either absent or of low intensity in female midstream urine samples. Indeed, a-defensins, which are an important part of the human antimicrobial defense [15, 16] , have been detected by SELDI-TOF-MS technology in urine [3] , as well as in culture supernatants of human 
CD8
+ T-cells [17] . The differences in the protein profile between first-void and midstream urines may be explained by urethral secretion of these proteins, which are then washed away by the first-void urine. Therefore, consistent urine protein profiling requires midstream urine samples for analysis, because first-void urine has a different protein composition than midstream urine and is more prone to protein degradation.
Blood was observed to be a major confounding variable affecting the normal urine protein profile. Not only did new peaks appear (i.e., peaks consistent with the masses of hemoglobin and albumin), but many of the normal peaks observed became undetectable. This is likely due to ion suppression by the blood proteins. Notably, even with a dilution of 10 lL blood in 64 mL diluted urine (1:6400 dilution), the peaks consistent with hemoglobin remained dominant. Clearly, such contamination invalidates any interpretation of the urine protein profile. Although centrifugation of the urine sample removes RBC, contamination with serum proteins will still continue to confound the urine protein profile.
Depending on fluid intake, the kidneys can concentrate urine to an output as low as 0.5 L/day, or dilute urine to almost 20 L/day. Under normal conditions, about 1-2 L urine are excreted per day. In a very dilute urine sample (urine creatinine 0.9 mmol/L), most of the proteins could not be detected on an NP20-chip. The threshold for a stable urine protein profile on an NP20-chip was a urine output of 2 L/day. Because every ProteinChip type has different binding capacities, the detection threshold has to be determined for every chip type individually.
In healthy individuals and under normal conditions, urine dilution, contamination with blood, and the portion of the urine specimen (first-void versus midstream) are the most obvious intrinsic factors that influence reproducibility and detection of proteins in profiles acquired by SELDI-TOF-MS. In addition, several transient "benign" states (e.g., fever, exercise) are known to increase the amount of proteins in urine [18, 19] by changing the size/charge selectivity of the glomerular barrier or by changing protein reabsorption/degradation through tubular cells [20, 21] . Whether different proteins appear in urine during these conditions has not yet been determined. However, these transient "benign" factors will need to be taken into account when comparing urine protein profiles from individuals in which such processes may be observed.
Protein quantification
Peak height and area under the peak have been used to reflect protein abundance [3, 22] . Although good correlation between the amount of a single protein alone or in a mixture with four other proteins and the peak intensity was found, it is questionable whether this remains true in a complex protein mixture (e.g., urine) due to many influencing factors like ion suppression and competition for binding sites on the ProteinChips. Therefore, care should be taken in comparing relative peak heights between two different urine protein profiles as an indicator of change in protein abundance under different circumstances (e.g., normal vs. pathologic state).
CONCLUSION
SELDI-TOF-MS offers many advantages for protein profiling in urine. First, only 5 to 10 lL of sample is needed for one analysis. Second, due to the simple chip preparation, many samples can be analyzed quickly. Third, the washing step removes most of the salts, which otherwise interfere with mass spectrometric analysis. And fourth, the impact of different chromatographic chemistries can be analyzed, which may allow one to find optimal purification conditions for a protein of interest in a short time with small amounts of sample. However, standardization of analysis conditions is essential, and both extrinsic and intrinsic factors must be taken into account for accurate data interpretation.
